NEWMEDS · The transfer of knowledge to facilitate the identification of novel pre-clinical active compounds for use as candidates in pharmaceutical drug discovery research

Линиите свързват координатора с партньорите. За проекти отпреди 2014 г. CORDIS не винаги дава точни координати. Тези точки са на ниво град или държава.

Накратко на български

Цел на проекта

Tripos Discovery Research Ltd. (TDR) is a contract research company supplying the pharmaceutical industry and is based in Bude, Cornwall. It is one of the largest employers in this Less Favoured Region, and is undergoing significant expansion to meet current business requirements. TDR has developed a synthetic chemistry / computer software based approach to medicinal drug discovery.This uses proprietary chemical library design technology (ChemSpaceTM), high throughput synthetic chemistry and sophisticated informatics. Support through a ToK Development Host Scheme is sought to enable TDR to develop it's own pre-clinical lead discovery programs, implement in-vitro biological and pharmacokinetic screening in-house and increase the scope of the research services that it offers.TDR has already made important contributions to several recent drug discovery projects and the knowledge that TDR intends to introduce is very complimentary to its current operations. New medicinal drugs are important in improving the quality of life for many people within the EU and produce economic benefits for those companies manufacturing them and for the community through improved healthcare. The pre-clinical lead discovery programs for which TDR is seeking knowledge transfer cover a broad area i.e. biological targets and medicinal chemistry related to the kinase, GPCR and protease families.The combination of this knowledge with TDR's existing strengths of high throughput chemistry and library design will provide chemistry based opportunities across a range of targets with potential applications and new drug opportunities in a number of important therapeutic areas (e.g. Cancer, Asthma, Arthritis, Alzheimer's disease). Additionally, and again building on existing TDR strengths, software and in-vitro biochemical techniques for predicting bioavailability and toxicity of synthetic organic compounds will be developed simultaneously.

Оригинален текст от CORDIS (на английски).

Участници

• EXELGEN LTD · BUDEКоординаторНиво градОбединеното кралство

Връзки

• Виж в CORDIS